Form 4 for VNRX VOLITIONRX LTD
Accepted 2024-05-24 00:00:00 ET · period of report 2024-05-23 · accession 0001477932-24-003295 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-24 | 2024-05-23 | VNRX | Retter Andrew | Chief Medical Off | A - Grant | $0.00 | +100.0K | 100.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-23 | A | A | 100,000 | $0.00 | 100,000 | D | — | — | (F1) In connection with his employment as Chief Medical Officer of Volition Diagnostics UK Limited, Dr. Retter received restricted stock units ("RSUs") subject to a 3-year vesting schedule, vesting as to 33,334 units, 33,333 units, and 33,333 units on each of May 23, 2025, May 23, 2026 and May 23, 2027, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. |